@article{RoyLachanceCohenetal.2019,
  author    = {Roy, Denis Claude and Lachance, Sylvie and Cohen, Sandra and Delisle, Jean-S{\´e}bastien and Kiss, Thomas and Sauvageau, Guy and Busque, Lambert and Ahmad, Imran and Bernard, Lea and Bambace, Nadia and Boum{\´e}dine, Radia S. and Guertin, Marie-Claude and Rezvani, Katayoun and Mielke, Stephan and Perreault, Claude and Roy, Jean},
  title     = {Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis},
  series = {British Journal of Haematology},
  volume    = {186},
  journal   = {British Journal of Haematology},
  number    = {5},
  doi       = {10.1111/bjh.15970},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-227075},
  pages     = {754-766},
  year      = {2019},
  abstract  = {Graft-versus-host disease (GVHD) is a major cause of transplant-related mortality (TRM) after allogeneic haematopoietic stem cell transplantation (HSCT) and presents a challenge in haploidentical HSCT. GVHD may be prevented by ex vivo graft T-cell depletion or in vivo depletion of proliferating lymphocytes. However, both approaches pose significant risks, particularly infections and relapse, compromising survival. A photodepletion strategy to eliminate alloreactive T cells from mismatched donor lymphocyte infusions (enabling administration without immunosuppression), was used to develop ATIR101, an adjunctive therapy for use after haploidentical HSCT. In this phase I dose-finding study, 19 adults (median age: 54 years) with high-risk haematological malignancies were treated with T-cell-depleted human leucocyte antigen-haploidentical myeloablative HSCT followed by ATIR101 at doses of 1 x 10(4)-5 x 10(6) CD3(+) cells/kg (median 31 days post-transplant). No patient received post-transplant immunosuppression or developed grade III/IV acute GVHD, demonstrating the feasibility of ATIR101 infusion for evaluation in two subsequent phase 2 studies. Additionally, we report long-term follow -up of patients treated with ATIR101 in this study. At 1 year, all 9 patients receiving doses of 0 center dot 3-2 x 10(6) CD3(+) cells/kg ATIR101 remained free of serious infections and after more than 8 years, TRM was 0\%, relapse-related mortality was 33\% and overall survival was 67\% in these patients.},
  language  = {en}
}